Search Results for "alcohol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for alcohol. Results 61 to 70 of 234 total matches.
See also: Novahistine
Nifurtimox (Lampit) for Chagas Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024 (Issue 1707)
: Consumption of alcohol during treatment is
contraindicated.
Dosage: 10-20 mg/kg ( ...
The FDA has approved the nitrofuran antiprotozoal drug
nifurtimox (Lampit – Bayer) for treatment of Chagas
disease (American trypanosomiasis) in children who
weigh ≥2.5 kg. Nifurtimox was previously available in
the US only through a CDC-sponsored Investigational
New Drug (IND) program.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):e123-4 doi:10.58347/tml.2024.1707h | Show Introduction Hide Introduction
Cisapride for Nocturnal Heartburn
The Medical Letter on Drugs and Therapeutics • Feb 04, 1994 (Issue 915)
, particularly alcohol, near bedtime and elevating the head of the bed or
sleeping on extra pillows. Drug ...
Cisapride (Propulsid - Janssen), a piperidinyl benzamide prokinetic drug, is now available in the USA for symptomatic relief of nocturnal heartburn due to gastroesophageal reflux disease. In Canada, cisapride is also marketed for treatment of gastroparesis.
Testosterone Patches for Hypogonadism
The Medical Letter on Drugs and Therapeutics • May 24, 1996 (Issue 975)
such as bilateral mumps orchitis, or toxic damage from alcohol,
heavy metals or chemotherapy. In primary ...
Men with primary or secondary hypogonadism require lifelong androgen replacement to prevent osteoporosis and maintain normal muscle mass, erythropoiesis and sexual function (AM Matsumoto, Endocrinol Metab Clin North Am, 23:857, 1994). Until recently, the standard treatment for male hypogonadism has been an intramuscular injection of a long-acting testosterone ester every two to three weeks, which leads to serum testosterone concentrations that are high for a few days, normal for a few days more, and then may be subnormal until the next dose. Two transdermal preparations of testosterone...
Prevention and Treatment of Heat Injury
The Medical Letter on Drugs and Therapeutics • Jul 21, 2003 (Issue 1161)
− Patients taking phenothiazines, butyrophenones, anticholinergics, diuretics,
beta-blockers or alcohol ...
Summer heat waves cause thousands of cases of heat-related illness in the US each year and hundreds of heat-related deaths, especially among the elderly. This review describes the contributing factors, clinical signs, and ways to prevent and treat heat injury.
Extended-Release Hydrocodone (Zohydro ER) for Pain
The Medical Letter on Drugs and Therapeutics • Jun 09, 2014 (Issue 1444)
.
Coadministration of 40% alcohol resulted in a 2.4-fold
increase in peak concentrations of hydrocodone ER.
Taking ...
The FDA has approved an extended-release oral formulation
of the opioid agonist hydrocodone (Zohydro ER –
Zogenix) for management of pain severe enough to
require continuous, long-term therapy and for which
alternative treatment options are inadequate. Zohydro ER
is the first single-ingredient hydrocodone product to be
marketed in the US. Hydrocodone has been available for
years in combination with acetaminophen (Vicodin, and
others) or ibuprofen (Vicoprofen, and others).
Gluten-Free Drugs for Celiac Disease Patients
The Medical Letter on Drugs and Therapeutics • Mar 10, 2008 (Issue 1281)
of
wheat. Gliadin is the alcohol-soluble, toxic fraction of
gluten. Gliadin, which is resistant ...
Celiac disease is a chronic autoimmune disorder caused by a genetic intolerance to gluten that occurs in about 1% of the population. The main form of treatment is a lifelong gluten-free diet.
L-Methylfolate (Deplin) for Depression and Schizophrenia
The Medical Letter on Drugs and Therapeutics • Apr 19, 2010 (Issue 1336)
monotherapy study (90 mg/day) in
depressed alcoholic patients with low red-cell folate
levels. At one week ...
L-methylfolate (Deplin — Pamlab) is a “medical food” marketed for adjunctive use in depression or schizophrenia in patients with suboptimal folate levels. It is available only by prescription.
Abuse-Deterrent Opioid Formulations
The Medical Letter on Drugs and Therapeutics • Aug 31, 2015 (Issue 1476)
oxycodone designed to deter abuse in a sample of prescription
opioid abusers. Drug Alcohol Depend 2014; 139 ...
Development of abuse-deterrent opioid products,
including reformulation of existing products, has
become a priority for drug manufacturers and public
health advocates. Three available opioid formulations,
OxyContin (Purdue), Embeda (Pfizer), and Hysingla ER
(Purdue), now include claims of abuse deterrence in
their package inserts.
Extended-Release Amantadine (Gocovri) for Dyskinesia in Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017 (Issue 1535)
of live vaccines.
Consumption of alcohol may increase the risk of CNS
adverse effects in patients taking ...
The FDA has approved an extended-release (ER)
capsule formulation of amantadine (Gocovri –
Adamas) for once-daily treatment of levodopa-induced
dyskinesia in patients with Parkinson's
disease (PD). It is the first product to be approved
in the US for this indication. Immediate-release (IR)
amantadine has been used off-label for years to
manage levodopa-induced dyskinesia.
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
, such
as alcohol, general anesthetics, phenothiazines,
sedative-hypnotics such as benzodiazepines or
barbiturates ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics